Unknown

Dataset Information

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.


ABSTRACT: Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical c

SUBMITTER: McLornan DP 

PROVIDER: S-EPMC6442950 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature